Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.40 |
| ▸ | KIF11 | P52732 | 10/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494633 | 1.00 | SIRT2 (0.40) | SIRT2KIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL20695568 | 0.79 | KIF11 (0.47) | KIF11 | |
| SCHEMBL17502351 | 0.79 | KIF11 (0.41) | SIRT2KIF11DRD2DRD4OPRM1 | |
| SCHEMBL13753316 | 0.78 | KIF11 (0.43) | KIF11 | |
| SCHEMBL29032286 | 0.78 | IDO1 (0.50) | SIRT2KIF11DRD2 | |
| SCHEMBL17493273 | 0.78 | CA14 (0.41) | KIF11HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL18291881 | 0.78 | CA14 (0.41) | SIRT2KIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL13753391 | 0.77 | KIF11 (0.43) | KIF11 | |
| SCHEMBL14708941 | 0.77 | CA14 (0.45) | KIF11HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL16141285 | 0.77 | CA14 (0.45) | SIRT2KIF11HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102525-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | SILBER B MICHAEL (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250255992-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | REILEY PHARMACEUTICALS INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20240358866-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | REILEY PHARMACEUTICALS INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20220133918-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | Reiley Pharmaceuticals, Inc. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255992-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | PTGES2, PTGES, OPRK1 | SIRT2 3317/4885KIF11 4386/4885HDAC3 2715/4885 |
| US-20260102525-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | OPRK1, OPRD1, OPRM1 | SIRT2 4049/4885KIF11 3993/4885HDAC3 888/4885 |
| US-20220133918-A1 | COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF | PTGES2, PTGES, OPRK1 | SIRT2 3317/4885KIF11 4386/4885HDAC3 2715/4885 |
| US-20240358866-A1 | NSAID-DERIVED CONJUGATE COMPOUNDS FOR IMAGING | PTGES2, PTGS2, PTGES | SIRT2 3135/4885KIF11 3969/4885HDAC3 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.